Copyright: ©Author(s) 2026.
Figure 3 Primary efficacy outcomes.
A-C: Dose comparison of olezarsen 80 mg vs 50 mg in regard to reduction in triglyceride level (A), non-high-density lipoproteins cholesterol level (B), and apolipoprotein C-III level (C).
- Citation: Patel V, Sohail R, Alam M, Chaudhry S, Mehdi S, Patel S, Patel R, Khattak R, Khan Z, Patel M. Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis. World J Cardiol 2026; 18(7): 121611
- URL: https://www.wjgnet.com/1949-8462/full/v18/i7/121611.htm
- DOI: https://dx.doi.org/10.4330/wjc.121611